MELATONIN ( DrugBank: Melatonin )

12 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	7
8	ハンチントン病	1
13	多発性硬化症／視神経脊髄炎	6
37	膿疱性乾癬（汎発型）	1
46	悪性関節リウマチ	2
49	全身性エリテマトーデス	1
72	下垂体性ADH分泌異常症	1
78	下垂体前葉機能低下症	1
90	網膜色素変性症	1
97	潰瘍性大腸炎	1
145	ウエスト症候群	1
202	スミス・マギニス症候群	3

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05307770 (ClinicalTrials.gov)	May 1, 2022	23/3/2022	Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder	Randomized, Double-Blind, Cross-Over Study Comparing the Efficacy of Immediate and Extended-Release Melatonin as a Supplement Affecting the Sleep Cycle in Patients With Parkinson Disease and Rapid Eye Movement Sleep Behavior Disorder	Rapid Eye Movement Sleep Behavior Disorder;Parkinson Disease	Dietary Supplement: Immediate Release Melatonin;Dietary Supplement: Extended Release Melatonin	Mayo Clinic	NULL	Recruiting	18 Years	N/A	All	50	N/A	United States
2	NCT04287543 (ClinicalTrials.gov)	May 2021	21/2/2020	Melatonin on Clock Genes in Parkinson's Disease	Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease	Parkinson Disease	Drug: Melatonin;Drug: Placebos	Instituto Mexicano del Seguro Social	NULL	Withdrawn	20 Years	N/A	All	0	Phase 2/Phase 3	Mexico
3	NCT02789592 (ClinicalTrials.gov)	July 2016	31/5/2016	Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease	A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease	REM Sleep Behavior Disorder;Parkinson Disease	Drug: Melatonin PR;Drug: Clonazepam;Drug: Melatonin PR placebo;Drug: Clonazepam placebo	Seoul National University Hospital	Kuhnil Pharmaceutical Co., Ltd.	Not yet recruiting	30 Years	N/A	Both	30	Phase 2	Korea, Republic of
4	NCT03258294 (ClinicalTrials.gov)	January 13, 2016	20/8/2017	Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease	Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial	Parkinson's Disease	Drug: Melatonin(Circadin®);Drug: Placebo Oral Tablet	KIMJisun	Kuhnil Pharmaceutical Co., Ltd.	Enrolling by invitation	55 Years	N/A	All	82	Phase 4	NULL
5	NCT02768077 (ClinicalTrials.gov)	January 2016	9/5/2016	Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease	Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial	Parkinson's Disease	Drug: Melatonin(Circadin®);Drug: Placebo	Kuhnil Pharmaceutical Co., Ltd.	NULL	Enrolling by invitation	55 Years	N/A	Both	100	Phase 4	NULL
6	EUCTR2014-002697-37-GB (EUCTR)	15/04/2015	19/03/2015	Study of Melatonin for treatment of Nocturia in PD	Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease - Study of Melatonin for treatment of Nocturia in PD	Parkinson's DiseaseNocturia MedDRA version: 17.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Circadin® Product Name: Melatonin Product Code: AS2 INN or Proposed INN: Melatonin	University College London	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 2	United Kingdom
7	NCT02359448 (ClinicalTrials.gov)	April 2015	4/2/2015	Melatonin for Nocturia in Parkinson's Disease	Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease	Parkinson's Disease;Nocturia	Drug: Melatonin	University College, London	NULL	Not yet recruiting	18 Years	N/A	Both	20	Phase 2	United Kingdom

先頭へ

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04421339 (ClinicalTrials.gov)	January 22, 2021	4/6/2020	Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study	Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study	Huntington Disease	Dietary Supplement: Melatonin;Other: Placebo	The University of Texas Health Science Center, Houston	Huntington's Disease Society of America	Recruiting	18 Years	75 Years	All	20	N/A	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04035889 (ClinicalTrials.gov)	September 23, 2019	25/7/2019	Melatonin for Sleep in MS	A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)	Multiple Sclerosis	Dietary Supplement: Melatonin;Dietary Supplement: Placebo	University of California, San Francisco	NULL	Completed	20 Years	70 Years	All	30	N/A	United States
2	NCT03498131 (ClinicalTrials.gov)	May 9, 2018	6/4/2018	Melatonin in Patients With Multiple Sclerosis (MS).	Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)	Relapsing Remitting Multiple Sclerosis	Drug: 3 mg Melatonin;Drug: 5 mg Melatonin	Providence Health & Services	NULL	Active, not recruiting	18 Years	65 Years	All	30	Early Phase 1	United States
3	EUCTR2012-004183-21-GB (EUCTR)	25/01/2013	14/12/2012	Melatonin for Nocturia in patients with Multiple Sclerosis	A randomized, double blind, placebo controlled, cross over trial of Melatonin for the treatment of nocturia in adults with progressive multiple sclerosis, with an open label, single-arm extension study - Melatonin for Nocturia in MS	Nocturia; Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Circadin Product Name: Circadin Product Code: N/A INN or Proposed INN: Circadin ( INN= Melatonin)	North Bristol NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	80	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
4	NCT02463318 (ClinicalTrials.gov)	September 2012	2/6/2015	The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects		Multiple Sclerosis;Oxidative Stress	Drug: Melatonin;Other: Hydrogen peroxide	Tehran University of Medical Sciences	NULL	Completed	20 Years	40 Years	Female	34	N/A	Iran, Islamic Republic of
5	NCT01718678 (ClinicalTrials.gov)	May 2012	28/10/2012	Effect of Melatonin on Multiple Sclerosis Related Fatigue	Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis	Fatigue	Drug: Melatonin;Drug: Placebo	Isfahan University of Medical Sciences	NULL	Completed	18 Years	55 Years	Both	44	Phase 2	Iran, Islamic Republic of
6	NCT01279876 (ClinicalTrials.gov)	October 2010	18/1/2011	Melatonin in Relapsing-Remitting Multiple Sclerosis Patients	Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients	Multiple Sclerosis, Relapsing-Remitting	Drug: Melatonin	Tehran University of Medical Sciences	NULL	Completed	20 Years	45 Years	Both	25	Phase 2	Iran, Islamic Republic of

先頭へ

37. 膿疱性乾癬（汎発型）

臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100044690	2021-04-01	2021-03-25	A randomized, double-blind, placebo-controlled clinical trial of melatonin combined with acitretin in the treatment of children with generalized pustular psoriasis	A randomized, double-blind, placebo-controlled clinical trial of melatonin combined with acitretin in the treatment of children with generalized pustular psoriasis	Generalized pustular psoriasis	Experimental group:Acitretin combined with melatonin;Control group:Acitretin combined with cooked flour;	Department of Dermatology, Children's Hospital of Chongqing Medical University	NULL	Recruiting	0	18	Both	Experimental group:15;Control group:15;		China

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000018816	2013/12/05	26/08/2015	Study on the relationship between arthritis and sleep disturbance	Study on the relationship between arthritis and sleep disturbance - Sleep study in arthritis	Rheumatoid Arthritis	Treatment with melatonin-mimetics, ramelteon. Treatment with biological disease-modifying anti-rheumatic drugs.	Shunichi Shiozawa	Rheumatic Diseases Center, Kohnan Kakogawa Hospital	Complete: follow-up complete	20years-old	Not applicable	Male and Female	200	Not applicable	Japan
2	NCT00287794 (ClinicalTrials.gov)	February 2006	6/2/2006	Quality of Sleep in Patients With Rheumatoid Arthritis	Study on the Quality of Sleep in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: diazepam, melatonin	Kobe University	NULL	Recruiting	17 Years	N/A	Both	1000		Japan

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900020803	2019-03-01	2019-01-19	Efficacy of Melatonin in patients with stable systemic lupus erythematosus complicated with insomnia: a single-center, randomized, double-blind, placebo-controlled clinical trial	Efficacy of Melatonin in patients with stable systemic lupus erythematosus complicated with insomnia: a single-center, randomized, double-blind, placebo-controlled clinical trial	systemic lupus erythematosus	intervention group:melatonin 6mg qn;control group:placebo qn;	Chinese Academy of Medical Sciences Peking Union Medical College Hospital	NULL	Pending	18	65	Both	intervention group:88;control group:88;	Phase 4	China

72. 下垂体性ADH分泌異常症

臨床試験数 : 41 / 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05319301 (ClinicalTrials.gov)	April 1, 2022	17/3/2022	Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)	Identification and Clinical Relevance of an Oxytocin Deficient State Following Melatonin Administration in Patients With Hypopituitarism: a Proof-of-concept, Physiopathological Study With a Control Group	Oxytocin Deficiency;Hypopituitarism;Hypothalamic Obesity;Pituitary Dysfunction;Central Diabetes Insipidus;Social Isolation	Dietary Supplement: Melatonin	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	NULL	Not yet recruiting	18 Years	N/A	All	40	N/A	Spain

78. 下垂体前葉機能低下症

臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05319301 (ClinicalTrials.gov)	April 1, 2022	17/3/2022	Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)	Identification and Clinical Relevance of an Oxytocin Deficient State Following Melatonin Administration in Patients With Hypopituitarism: a Proof-of-concept, Physiopathological Study With a Control Group	Oxytocin Deficiency;Hypopituitarism;Hypothalamic Obesity;Pituitary Dysfunction;Central Diabetes Insipidus;Social Isolation	Dietary Supplement: Melatonin	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	NULL	Not yet recruiting	18 Years	N/A	All	40	N/A	Spain

90. 網膜色素変性症

臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-002436-82-ES (EUCTR)	13/12/2012	22/10/2012	Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa	Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa	To evaluate the sleep quality in patients with Retinitis Pigmentosa;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: CIRCADIN 2 mg comprimidos de liberación prolongada Product Name: Circadin 2 mg INN or Proposed INN: Not answered Other descriptive name: MELATONIN	Isabel Pinilla Lozano	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Spain

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00790478 (ClinicalTrials.gov)	January 2009	12/11/2008	Melatonin and Ulcerative Colitis: A Pilot Clinical Trial	Melatonin and Ulcerative Colitis: A Pilot Clinical Trial	Ulcerative Colitis	Drug: Melatonin;Other: Placebo	Emory University	NULL	Terminated	18 Years	69 Years	All	3	Phase 2	United States

145. ウエスト症候群

臨床試験数 : 43 / 薬物数 : 52 - (DrugBank : 15) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 26

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000036208	2020-10-31	2020-08-21	Melatonin as add-on treatment for infantile spasms	Melatonin supplementation in the treatment of infantile spasms: a randomized placebo-controlled triple-blind trial	Infantile spasm	melatonin group:add melatonin;placebo group:add placebo;	Department of Pediatrics, The First Medical Center, General Hospital of the People's Liberation Army of China	NULL	Recruiting	3?	2	Both	melatonin group:35;placebo group:35;		China

202. スミス・マギニス症候群

臨床試験数 : 9 / 薬物数 : 10 - (DrugBank : 5) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03492970 (ClinicalTrials.gov)	March 7, 2018	1/3/2018	Melatonin in Adults With SMS	Characterization of Behavioral Disorders and 24 H-melatonin Level in Adults With Smith Magenis Syndrome	Smith Magenis Syndrome	Biological: Hourly dosing of the nychtemeral secretion of melatonin	Hôpital le Vinatier	Hospices Civils de Lyon	Completed	18 Years	65 Years	All	10	N/A	France
2	NCT00506259 (ClinicalTrials.gov)	July 17, 2007	21/7/2007	Treatment Strategies for Children With Smith-Magenis Syndrome	A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)	Developmental Delay Disorders;Chromosome Deletion;Mental Retardation;Sleep Disorders, Circadian Rhythm;Self Injurious Behavior	Drug: dTR Melatonin (NIH CC PDS);Device: Phototherapy (Bright Light);Drug: Melatonin CR	National Human Genome Research Institute (NHGRI)	NULL	Completed	3 Years	45 Years	All	23	Phase 1	United States
3	NCT00691574 (ClinicalTrials.gov)	September 1998	30/5/2008	Melatonin Levels in Smith Magenis Syndrome (SMS)	Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot Study	Chromosome Disorders	Dietary Supplement: Melatonin;Device: Enviro-light artificial light box	Oregon Health and Science University	NULL	Terminated	3 Years	85 Years	All	5	N/A	United States

先頭へ